Keros Therapeutics (KROS) vs MacroGenics (MGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MacroGenics (MGNX) has outperformed Keros Therapeutics (KROS) over the past year, gaining 99.4% versus a loss of 27.1%. Over five years, KROS leads with a -70.1% price change compared with -82.0% for MGNX. MacroGenics is the larger company by market cap ($238.2 million vs $236.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KROS | MGNX |
|---|---|---|
| Share price | $11.95 | $3.74 |
| Market cap | $236.93M | $238.24M |
| 1-day change | +2.66% | +5.35% |
| YTD return | -42.83% | +120.50% |
| 1-year return | -27.07% | +99.44% |
| 5-year return | -70.15% | -82.02% |
| EPS (TTM) | $-3.22 | $-1.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.55 | $5.08 |
| 52-week low | $9.69 | $1.29 |
| Distance from 52-week high | -47.01% | -26.38% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +65.94% | +113.90% |
| Average volume | 194.05K | 622.92K |
| Shares outstanding | 19.83M | 63.70M |
| Employees | 92 | 293 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGNX has outperformed KROS by 126.5 percentage points over the past year.
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About MacroGenics
MGNX stock →MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
KROS vs MGNX FAQ
Which is bigger, Keros Therapeutics or MacroGenics?
MacroGenics (MGNX) is larger, with a market capitalization of $238.24M compared with $236.93M for Keros Therapeutics (KROS).
Which stock has performed better over the past year, KROS or MGNX?
MGNX returned +99.44% over the past 12 months, compared with -27.07% for KROS (price return, excluding dividends). Past performance does not predict future results.
Are Keros Therapeutics and MacroGenics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.